SONY

Product Data Sheet

Alexa Fluor® 700 anti-mouse CD73

Catalog # / Size: 1236150 / 100 µg
1236145 / 25 µg

Clone: TY/11.8

Isotype: Rat IgG1, κ

Immunogen: CHO cells transfected with mouse CD73

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Alexa Fluor® 700 under optimal conditions. The solution is free of unconjugated Alexa Fluor® 700.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Concentration: 0.5 mg/ml



C57BL/6 mouse splenocytes were first treated with TruStain FcX™ (anti-mouse CD16/32) antibody and True-Stain Monocyte Blocker™. Cells were then stained with CD3ε PE and CD73 (clone TY/11.8) Alexa Fluor® 700 (left) or rat IgG1, κ Alexa Fluor® 700 isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

* Alexa Fluor® 700 has a maximum emission of 719 nm when it is excited at 633 nm / 635 nm. Prior to using Alexa Fluor® 700 conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.

Application Notes: Additional reported applications (for the relevant formats) include: immunohistochemistry of acetone-fixed frozen tissue sections.

Application References:

1. Yamshita Y, *et al* 1998. *Eur. J. Immunol.* 28:2981.
2. Bentley JK, *et al.* 2010. *Respir. Res.* 11:127. (IHC-P)

Description: CD73 (ecto-5'-nucleotidase) is a 69 kD GPI-anchored surface protein. In mice, expression of CD73 in bone marrow is restricted to $CD11b^+$ myeloid cells. In spleen, it is largely expressed on T cells.

Antigen References:

1. Yamashita Y, *et al* 1998. *Eur. J. Immunol.* 28:2981.
2. Resta R, *et al.* 1998. *Immunol. Rev.* 161:95.